ITMR - Itamar Medical sees Q4 revenue above consensus

Itamar Medical (ITMR) +2% premarket, expects Q4 revenue in the range of $12.5M-$12.8M, reflecting growth of 28%-31% and above consensus of $11.71M; WatchPAT revenue of $12M-$12.3M, representing growth of 32%-35%; U.S. WatchPAT revenue of $10M-$10.3M, representing growth of 36% to 40%.FY2020 revenue to grow ~31% to $40.8M-$41.1M vs. consensus of $39.78M. “Following a strong Q3, we were pleased to see that trend continue into the fourth quarter, largely driven by our U.S. core sleep business from both existing customers as well as new customers nationwide. We continue to believe that the shift to home-based care has accelerated our plans of reaching many of the 80% undiagnosed patients estimated to have sleep apnea in the U.S. and other parts of the world,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical. Q4 results will be out on March 2.

For further details see:

Itamar Medical sees Q4 revenue above consensus